Why the study?
Does pradigastat reduce triglyceride levels in patients with familial chylomicronemia syndrome?
Population
6 patients with familial chylomicronemia syndrome (FCS)
Comparison
Pradigastat once daily oral dosing at 20 mg, 40… vs Baseline lipid assessments
Design
Case_series, open-label
Follow-up
21 days per treatment period
Authors
Loading...
Hypothesis-generating for pradigastat in FCS; leaves open efficacy, safety, and need for RCTs before practice change.
Does pradigastat reduce triglyceride levels in patients with familial chylomicronemia syndrome?
Pradigastat substantially reduces fasting and postprandial triglyceride levels in patients with familial chylomicronemia syndrome and is well tolerated.
Meyers et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: